Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, E. David Crawford, Judd Moul, Jens-Kristian Jensen, Tine Kold Olesen, Bo-Eric PerssonVolume:
57
Year:
2010
Language:
english
Pages:
7
DOI:
10.1016/j.eururo.2009.11.029
File:
PDF, 350 KB
english, 2010